EuroBiotech: More Articles of Note


> Zambon completed the acquisition of Breath Therapeutics. The takeover gives Zambon control of a phase 3 treatment for a rare fatal respiratory disease. Release 

> Transgene received U.K. regulatory clearance to trial its TG6002 oncolytic virus. Statement 

> BiomX secured itself a U.S. stock listing through a deal with Chardan Healthcare Acquisition. Release

Submissions Open

Fierce Innovation Awards: Life Sciences Edition 2020

Submit your entry to demonstrate innovative technologies and services that have the potential to make the greatest impact for biotech and pharma companies.

> Nasdaq told Motif Bio that it no longer meets the minimum requirements for listing. Motif Bio has until mid-January to regain compliance. Statement 

> The AMR Centre struck a deal with Shionogi for anti-virulence program COT-143. The plan is to run clinical trials of the asset next year. Release 

> Novo Holdings’ Repair impact fund invested $10 million in Curza and Spero. Statement 

Suggested Articles

German researchers uncovered 28 antibodies that neutralize COVID-19 and are working with Boehringer Ingelheim to advance them into clinical testing.

Oragenics is ending a phase 2 study of its oral mucositis drug, yanking its IND application and switching its focus to a COVID-19 vaccine.

The vehicle, which Blackstone claims is the largest life sciences private fund, has committed close to $1 billion to companies including Alnylam.